trending Market Intelligence /marketintelligence/en/news-insights/trending/mItV0j0E5icSHrZ388OElg2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Pediapharm changes name to Medexus Pharmaceuticals


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


COVID-19 Impact & Recovery: Private Equity

Pediapharm changes name to Medexus Pharmaceuticals

Pediapharm Inc. shareholders approved a change in the company's name to Medexus Pharmaceuticals Inc. on Dec. 12.

Shareholders also approved a 1-for-15 share consolidation of the company's stock which will begin trading on a post-consolidation and post-name change basis on the TSX Venture Exchange under the MDP symbol in the near future.

The company decided to change its name following its acquisitions of Medexus Inc., which is focused on rheumatology, women's health and dermatology, and Medac Pharma Inc., which sells rheumatoid arthritis therapy Rasuvo.

Canada's Medexus will operate as a specialty pharmaceutical company.